Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 9/20 | 0.67 |
| ▸ | CASP2 | P42575 | 1/20 | 0.59 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.55 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.55 |
| ▸ | NAAA | Q02083 | 1/20 | 0.55 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.52 |
| ▸ | RRM1 | P23921 | 1/20 | 0.52 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3789783 | 1.00 | EPHX1 (0.67) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL292693 | 1.00 | EPHX1 (0.67) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL3055110 | 1.00 | EPHX1 (0.67) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL19468503 | 1.00 | EPHX1 (0.67) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL2185171 | 1.00 | EPHX1 (0.67) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL19468457 | 1.00 | EPHX1 (0.67) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL76613 | 1.00 | EPHX1 (0.67) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL944633 | 1.00 | EPHX1 (0.67) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL19468513 | 1.00 | EPHX1 (0.67) | EPHX1CASP2ZDHHC20ZDHHC2NAAA | |
| SCHEMBL1820932 | 1.00 | EPHX1 (0.67) | EPHX1CASP2ZDHHC20ZDHHC2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1347 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12285735-B2 | Preparation method and use method of material for deep purification of HF electronic gas | ZHEJIANG BRITECH CO., LTD. (CN) | 2025-04-29 | — | — | US | claimed |
| CN-116635396-A | Pt (IV) chemotherapeutic prodrugs and their controlled release for treating tumors | 北京大学 | 2023-08-22 | — | — | CN | claimed |
| US-20220355267-A1 | Preparation Method and Use Method of Material for Deep Purification of HF Electronic Gas | ZHEJIANG BRITECH CO., LTD. (CN) | 2022-11-10 | — | — | US | claimed |
| CN-111422870-B | Preparation and application method of HF electronic gas deep purification material | 浙江博瑞电子科技有限公司 | 2021-04-09 | — | — | CN | claimed |
| CN-111422870-A | Preparation and application method of HF electronic gas deep purification material | 浙江博瑞电子科技有限公司 | 2020-07-17 | — | — | CN | claimed |
| US-9935269-B2 | Electroluminescence element | Konica Minolta, Inc. (JP) | 2018-04-03 | — | — | US | claimed |
| CN-106560235-A | Preparation method and application of organic isocyanate-and-isorhodanate modified attapulgite | 淮阴师范学院 | 2017-04-12 | — | — | CN | claimed |
| EP-2916820-A1 | DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS | Rochal Industries, LLC (US) | 2015-09-16 | — | — | EP | claimed |
| US-8852648-B2 | Delivery of biologically-active agents using volatile, hydrophobic solvents | ROCHAL INDUSTRIES, LLP (US) | 2014-10-07 | — | — | US | claimed |
| WO-2014074289-A1 | DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS | ROCHAL INDUSTRIES, LLP (US) | 2014-05-15 | — | — | WO | claimed |
| US-20140127320-A1 | DELIVERY OF BIOLOGICALLY-ACTIVE AGENTS USING VOLATILE, HYDROPHOBIC SOLVENTS | ROCHAL INDUSTRIES, LLP (US) | 2014-05-08 | — | — | US | claimed |
| CN-1918212-A | Highly functional, highly branched polyureas | BASF AG (DE) | 2007-02-21 | — | — | CN | claimed |
| US-5096978-A | Butadiene polymers having improved scorch delay and fast cure rates; tires; treads | MONSANTO COMPANY (US) | 1992-03-17 | — | — | US | claimed |
| EP-0364428-A1 | Vulcanizable synthetic rubber compositions cure-activated by substituted ureas | Monsanto Company (US) | 1990-04-18 | — | — | EP | claimed |
| JP-6320862-A | — | — | None | — | — | JP | disclosed |
| EP-4683713-A1 | DEUTERATED P2X3 MODULATORS | GlaxoSmithKline Intellectual Property (No.3) Limited (GB) | 2026-01-28 | — | — | EP | disclosed |
| US-12485125-B2 | Treatment with P2X3 modulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 3) LIMITED (GB) | 2025-12-02 | — | — | US | disclosed |
| US-3959127-A | Biodegradation of oil on water surfaces | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1976-05-25 | — | — | US | disclosed |
| US-3957774-A | POLYMERIZE ON HAIR, HAIR CONDITIONERS | L'OREAL (FR) | 1976-05-18 | — | — | US | disclosed |
| US-3956366-A | PREPARATION OF AZO AND HYDRAZINE COMPOUND | PENNWALT CORPORATION (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12485125-B2 | Treatment with P2X3 modulators | P2RX3, P2RX4, P2RX2 | EPHX1 117/4885CASP2 2236/4885ZDHHC20 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.